Market-Moving Exclusives Archives - Page 7 of 22

2 minute read

EXCLUSIVE: Foremost Lithium Sets Winter Drilling Agenda At Jean Lake Lithium/Gold Property

December 19, 9:00 AM

Foremost Lithium Resource & Technology Ltd. (NASDAQ: FMST) announces its upcoming winter drilling plans at the Jean Lake Lithium/Gold Property near Snow Lake in Manitoba, Canada.

FMST

2 minute read

Uber Stock Is Near New Highs, Here Are 3 Reasons Why

By Surbhi Jain

December 15, 12:55 PM

Uber stock surged 127.52% compared to the broad market S&P 500 Index, and recorded a new 52-week high on Dec. 12 trading.

DPZ

1 minute read

Visa’s All-Time High: E-Payments Propel Stock With Bullish Chart Indicators

By Surbhi Jain

December 14, 11:17 AM

Visa Inc (NYSE:V) stock hit an all-time-high of $262.48, driven by cash-to-electronic payments switch, operating leverage, and strategic bandwidth. Technicals show a bullish trend.

2 minute read

Broadcom Stock Hits All-Time High: Golden Cross Hints At Further Upside

By Surbhi Jain

December 14, 9:56 AM

Broadcom Inc's (AVGO) stock hit an all-time high of $1,099.78 on Wednesday, driven by Q4 earnings beat & doubling AI sales forecast. Technicals show a golden cross indicating a bullish trend.

AVGO

1 minute read

Exclusive: No Lithium Without Water – Canter Resources Obtains Water Permits Advancing Columbus Lithium-Boron Project

By Melanie Schaffer

December 14, 8:00 AM

Canter Resources Corp. (CSE:CRC) (OTCMKTS: CNRCF) has cleared a significant hurdle in its quest for lithium as it announced the approval of formal water permits by the Nevada Division of Water Rights (NDWR).

CNRCF

2 minute read

Macy’s Stock Is Running: 3 Catalysts That May Be Boosting The Retailer

By Surbhi Jain

December 11, 12:28 PM

Macy's received a buyout offer from an investor consortium, including Arkhouse Management and Brigade Capital Management.

1 minute read

EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year

By Vandana Singh

December 11, 8:30 AM

Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for

ALZN